P75NTR(NBP)-FC fusion protein and its medical use

The p75NTR(NBP)-Fc fusion protein addresses the limitations of current treatments by selectively binding to NT3, improving solubility, stability, and half-life, effectively reducing pain and modifying osteoarthritis progression.

WO2026093764A1 Publication Date: 2026-05-07LEVICEPT LTD
3 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2025/052395
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-01
Filing Date
2025-10-31
Publication Date
2026-05-07

AI Technical Summary

Technical Problem

Current treatments for pain and osteoarthritis, such as selective antibodies targeting neurotrophin receptors, have limitations in efficacy and specificity, particularly for conditions like osteoarthritis, where neurotrophins play a significant role.

Method used

A p75NTR neurotrophin binding protein (NBP)-Fc fusion protein is developed, comprising a p75NTR portion with high homology to specific sequences and an immunoglobulin Fc portion connected by a flexible linker, which selectively binds to NT3 with high affinity, modulating neurotrophin activity and providing therapeutic benefits.

Benefits of technology

The fusion protein effectively reduces pain and modifies the progression of osteoarthritis by selectively binding to NT3, enhancing solubility, stability, and serum half-life, thereby reducing the frequency of dosing and potential side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR(NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR(NBP)-Fc fusion protein is for use in the treatment of pain and / or a symptom of pain.
Need to check novelty before this filing date? Find Prior Art